Policy Statement

Diagnosis

Unattended (Unsupervised) Home Sleep Study

Blue Shield of California (BSC) requires an unattended (unsupervised) home sleep study as the initial study for the screening for and diagnosis of obstructive sleep apnea (OSA, see definition in Policy Guidelines) in adults, unless contraindicated.

Contraindications to home sleep studies include, but are not limited to:
- Central sleep apnea
- Heart failure
- Chronic pulmonary disease
- Obesity hypoventilation syndrome
- Neuromuscular disorders with sleep-related symptoms (see Policy Guidelines section)
- Injurious or potentially injurious parasomnias
- Narcolepsy

Note: This home sleep study should include a minimum of 4 recording channels (including oxygen saturation, respiratory movements, airflow, and electrocardiogram [ECG] or heart rate) because the BSC payment approval for all OSA therapeutic devices (including initial positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP] and oral appliances) is based on the performance of an initial four-channel diagnostic study.

Unattended home sleep studies are considered investigational in children (younger than 18 years of age).

Repeated unattended (unsupervised) home sleep studies with a minimum of 4 recording channels (including oxygen saturation, respiratory movement, airflow, and ECG or heart rate) may be considered medically necessary in adult patients under either of the following circumstances:
- To assess efficacy of surgery or oral appliances or devices
- To reevaluate the diagnosis of OSA and need for CPAP (e.g., if there is a significant change in weight or change in symptoms suggesting that CPAP should be discontinued)

Supervised Polysomnography (PSG) in a Sleep Laboratory

Supervised polysomnography (PSG) performed in a sleep laboratory may be considered medically necessary in patients considered at moderate or high probability of OSA in any of the following situations:
- Pediatric patients (i.e., less than 18 years of age)
- A previous home study failed to establish the diagnosis of OSA in a patient with a high probability of OSA
- A previous home study was technically inadequate
- Failure of resolution of symptoms or recurrence of symptoms during treatment
- Assuming the initial diagnostic study was a PSG, to reevaluate the diagnosis of OSA and need for initiation, reinitiation, or continued CPAP (e.g., if there is a significant change in weight or change in symptoms suggesting that CPAP should be retitrated or possibly discontinued)
- When testing is done to rule out other sleep disorders such as injurious or potentially injurious parasomnias, or narcolepsy (often done prior to multiple sleep latency testing)
- Presence of a known comorbidity that might alter ventilation or decrease the accuracy of a home sleep study, including, but not limited to significant, ongoing symptoms of
heart failure, stroke/transient ischemic attack, coronary artery disease, tachycardic or bradycardic arrhythmias, neuromuscular disease, chronic pulmonary disease, or obesity hypoventilation syndrome. If the initial diagnosis of OSA was based on a PSG, a PSG may be done if retesting is required.

A repeated supervised PSG performed in a sleep laboratory may be considered medically necessary in patients who meet criteria for an in-laboratory PSG under any of the following circumstances:

- To initiate and titrate CPAP in adult patients who have either of the following (See below note):
  - An Apnea/Hypopnea Index (AHI) of at least 15 events per hour
  - An AHI of at least 5 events per hour in a patient with excessive daytime sleepiness or hypertension
- To initiate and titrate CPAP in children:
  - In pediatric patients, an AHI greater than or equal to 1.0 events per hour is considered abnormal, and an AHI of 10 or more may be considered severe
- To assess efficacy of surgery or oral appliances/devices if a home sleep study could not confirm or disprove OSA
- To assess efficacy of adenotonsillectomy in patients under the age of 18

Note: A split-night study, in which moderate to severe OSA is documented during the first portion of the study using PSG, followed by CPAP during the second portion of the study, eliminates the need for a second study to titrate CPAP and is preferred whenever possible (See Policy Guidelines section for criteria to perform a split-night study).

Supervised or unattended home sleep studies that do not meet the above criteria are considered not medically necessary.

Auto-adjusting positive airway pressure (APAP) may be considered medically necessary for the titration of pressure in adult patients with clinically significant OSA defined as those patients who have either of the following:

- An Apnea/Hypopnea Index (AHI) or Respiratory Disturbance Index (RDI) of at least 15 events per hour
- An AHI or RDI of at least 5 events per hour in a patient with excessive daytime sleepiness or hypertension

The use of an abbreviated daytime sleep study (PAP-NAP) is considered investigational.

Multiple sleep latency testing is considered not medically necessary in the initial workup of OSA.*

Replacement of a PAP device (beyond the warranty period) requires documentation of the reason for replacement, use, and benefit from the device; however, a repeat sleep study or trial period is not required.

**Medical Management**

CPAP may be considered medically necessary in adult or pediatric patients with clinically significant OSA, provided that diagnosis was based on the performance of a four-channel (or greater) diagnostic study.

Bilevel positive airway pressure (BiPAP) or APAP may be considered medically necessary in patients with both of the following:

- Clinically significant OSA
- One of the following:
  - Who have failed a prior trial of CPAP
  - Whom BiPAP is found to be more effective in the sleep lab
Intraoral appliances (tongue-retaining devices or mandibular advancing/positioning devices) may be considered medically necessary in adult patients with clinically significant OSA when all of the following conditions have been met:

- OSA, defined by an AHI of at least 15 events per hour or an AHI of at least 5 events per hour in a patient with excessive daytime sleepiness or hypertension
- Initial or continued use of CPAP is clinically not indicated or is refused by the patient
- The device is prescribed by a treating physician
- The device is custom-fitted by qualified dental personnel
- There is absence of significant temporomandibular dysfunction or periodontal disease

Note: CPAP has been shown to have greater effectiveness than oral appliances in general. This difference in efficacy is more pronounced for patients with severe OSA, as oral appliances have been shown to be less efficacious in patients with severe OSA than they are in patients with mild-moderate OSA. Therefore, it is particularly important that patients with severe OSA should have an initial trial of CPAP and that all reasonable attempts are made to continue treatment with CPAP, prior to the decision to switch to an oral appliance.

Nasal expiratory positive airway pressure, oral pressure therapy devices, and mandibular/palatal expansion devices for the treatment of OSA are considered investigational.

*See Blue Shield of California Medical Policy: Polysomnography for Non-Respiratory Sleep Disorders

**Policy Guidelines**

**Definition of Obstructive Sleep Apnea**

Obstructive sleep apnea (OSA) syndrome is characterized by repetitive episodes of upper airway obstruction due to the collapse of the upper airway during sleep. Clinically significant (moderate or severe) OSA in adults is diagnosed by either home or lab-based sleep studies demonstrating an Apnea/Hypopnea Index (AHI) or Respiratory Disturbance Index (RDI) of at least 15 events per hour or an AHI or RDI of at least 5 events per hour in a patient with excessive daytime sleepiness as determined by standard questionnaires such as the Epworth Sleepiness Scale or the STOP-BANG survey or hypertension.

The following are generally accepted measures of OSA severity:

- **None/minimal**: AHI or RDI less than 5 events/hour
- **Mild**: AHI or RDI greater than or equal to 5 events/hour but less than 15 events/hour
- **Moderate**: AHI or RDI greater than or equal to 15 events/hour but less than 30 events/hour
- **Severe**: AHI or RDI greater than or equal to 30 events/hour

**Neuromuscular Diseases Contraindicating Home Sleep Studies**

- Amyotrophic lateral sclerosis (ALS)
- Charcot-Marie-Tooth disease
- Multiple sclerosis
- Muscular dystrophy
- Myasthenia gravis
- Myopathy, severe
- Myositis, including polymyositis and dermomyositis
- Peripheral neuropathy, severe
- Spinal muscular atrophy

**Risk Factors for Obstructive Sleep Apnea**

Although not an exclusive list, patients with any two of the following symptoms are considered to be at high risk for OSA:

- Habitual snoring
• Observed apneas
• Excessive daytime sleepiness
• A body mass index (BMI) greater than 35 kg/m²

If no bed partner is available to report snoring or observed apneas, other signs and symptoms suggestive of OSA, (e.g., age of the patient, male gender, thick neck, craniofacial or upper airway soft tissue abnormalities, or hypertension) may be considered. Objective clinical prediction rules are being developed; however, at the present time, risk assessment is based primarily on clinical judgment.

Sleep Questionnaires
The following sleep questionnaires (all self-answered by the patient) attempt to quantify the probability of having OSA:
• Epworth Sleepiness Scale: Comprised of eight questions with a maximum score of 24. A score of greater than 10 indicates moderate to high probability of OSA.
• Berlin Questionnaire: Comprised of 10 questions and three scoring categories. Two or more positive categories indicate a high probability of OSA.
• STOP-BANG: Comprised of eight questions. A “yes” answer on three or more questions indicates a high probability of OSA. The STOP-BANG questionnaire is a method developed for non-sleep specialists to assess the signs and symptoms of OSA (Snore, Tired, Observed apnea, blood Pressure, BMI, Age, Neck, Gender) and has been shown to have 97% sensitivity and a negative predictive value of 96% (specificity of 33%) for the identification of patients with severe OSA (Apnea/Hypopnea Index [AHI] score greater than 30 events per hour). Overnight oximetry has been used by some sleep specialists as a component of the risk assessment but is not adequate for the diagnosis of OSA. Therefore, a follow-up polysomnography (PSG) or home sleep study would still be required to confirm or exclude a diagnosis of OSA.

Obstructive Sleep Apnea in Children
The presentation of OSA in children may differ from that of adults. Children frequently exhibit behavioral problems or hyperactivity rather than daytime sleepiness. Obesity is defined as a body mass index (BMI) greater than the 90th percentile for the weight/height ratio. Although the definition of severe OSA in children is not well established, an AHI greater than or equal to 1.0 events per hour is considered abnormal (an AHI score of greater than or equal to 10 events per hour may be considered severe). In addition, the first-line treatment in children is usually adenotonsillectomy. Continuous positive airway pressure (CPAP) is an option for children who are not candidates for surgery or who have an inadequate response to surgery.

Bariatric Surgery Patients
Screening for OSA should be performed routinely in patients scheduled for bariatric surgery, due to the high prevalence of OSA in this population. The optimal screening approach is not certain. An in-laboratory PSG or home sleep study is the most accurate screening method. Some experts recommend a symptom-based screening instrument, followed by PSG in patients who exceed a certain threshold, as an alternative to performing PSG in all patients. It should be noted that there is a high prevalence of obesity hypoventilation syndrome in patients who are candidates for bariatric surgery. Therefore, obesity hypoventilation syndrome should be ruled out prior to home sleep testing in this population.

Multiple Sleep Latency Test
The multiple sleep latency test (MSLT) is an objective measure of the tendency to fall asleep in the absence of alerting factors, while the maintenance of wakefulness test (MWT) is an objective measure of the ability to stay awake under soporific conditions (used to assess occupational safety). The MSLT and MWT are not routinely indicated in the evaluation and diagnosis of OSA or in assessment of change following treatment with continuous positive airway pressure (CPAP). The MSLT may be indicated as part of the evaluation of patients with suspected narcolepsy to confirm the diagnosis (often characterized by cataplexy, sleep paralysis, and
hypnagogic/hypnopompic hallucinations) or to differentiate between suspected idiopathic hypersomnia and narcolepsy. Narcolepsy and OSA can co-occur. Because it is not possible to differentiate the excessive sleepiness caused by OSA and narcolepsy, the OSA should be treated before confirming a diagnosis of narcolepsy with the MSLT. See Blue Shield of California Medical Policy: Polysomnography for Non-Respiratory Sleep Disorders

**Specialist Training**

The medical professional who is interpreting a polysomnogram or home sleep study should have training in sleep medicine and should review the raw data from PSG and home sleep studies in order to detect artifacts and data loss. In addition, the treatment of patients diagnosed with OSA should be initiated and monitored by a professional with training in sleep medicine. It is important to monitor symptoms and adherence to positive airway pressure (PAP) treatment, e.g., review of symptoms and device utilization between 30 and 90 days.

**Split-Night Studies**

American Academy of Sleep Medicine (AASM) Practice Parameters (2005) indicate that a split-night study (initial diagnostic PSG followed by CPAP titration during PSG on the same night) is an alternative to one full night of diagnostic PSG followed by a second night of titration if the following 4 criteria are met:

a. An AHI of at least 40 events per hour is documented during a minimum of 2 hours of diagnostic PSG. Split-night studies may sometimes be considered at an AHI of 20 to 40 events per hour, based on clinical judgment (e.g., if there are also repetitive long obstructions and major desaturations). However, at AHI values below 40, determination of CPAP level requirements, based on split-night studies, may be less accurate than in full-night calibrations.

b. CPAP titration is carried out for more than 3 hours (because respiratory events can worsen as the night progresses).

c. PSG documents that CPAP eliminates or nearly eliminates the respiratory events during rapid eye movement (REM) and non-REM (NREM) sleep, including REM sleep with the patient in the supine position.

d. A second full night of PSG for CPAP titration is performed if the diagnosis of a sleep-related breathing disorder (SRBD) is confirmed, but criteria b and c are not met.

**Categorization of Polysomnography and Portable Monitoring**

There is not full correspondence between the CPT codes and the most current categorization scheme for the different types of studies. In the 2005 practice parameters of AASM, there are 4 types of monitoring procedures: type 1, standard attended in-lab comprehensive PSG; type 2, comprehensive portable PSG; type 3, modified portable sleep apnea testing (also referred to as cardiopulmonary sleep studies), consisting of 4 or more channels of monitoring; and type 4, continuous single or dual bioparameters, consisting of 1 or 2 channels, typically oxygen saturation, or airflow. Types 1 and 2 would be considered polysomnographic studies, and types 3 and 4 would be considered polygraphic sleep studies. The terms sleep studies and PSG are often used interchangeably. CPT coding makes a distinction between sleep studies that do not include electroencephalographic (EEG) monitoring, and PSG, which includes EEG monitoring. PSG is usually conducted in a sleep laboratory and attended by a technologist, but may also be conducted with type 2 portable monitoring. The type of study is further characterized as attended (supervised) or unattended by a technologist. Home or portable monitoring implies unattended sleep studies, typically conducted in the patient’s home. There are no specific codes for remotely monitored home sleep studies. They would likely be reported with the CPT code for the sleep study with the GT modifier (“via interactive audio and video telecommunications systems”) appended. There is no CPT code for “unattended” PSG.

Cardiorespiratory sleep studies without EEG may be called polygraphic studies and can either be attended or unattended by a technologist. The CPT codes 95807 and 95806 distinguish polygraphic sleep studies that are attended or unattended, but there are no codes that distinguish between type 3 and type 4 sleep studies. A wide variety of portable monitors and
proprietary automated scoring systems are being tested and marketed, but the optimum combination of sensors and scoring algorithms is currently unknown. Current recommendations are that the portable monitoring device have 4 channels (oxygen saturation, respiratory effort, respiratory airflow, and heart rate) and allow review of the raw data. Type 4 monitors with fewer than 3 channels are not recommended due to reduced diagnostic accuracy and higher failure rates. As with attended PSG, it is important that the raw data from home sleep studies be reviewed by a professional with training in sleep medicine in order to detect artifacts and data loss.

**Continuous Positive Airway Pressure (CPAP)**

Note: Blue Shield of California follows the Medicare Durable Medical Equipment Regional Carrier (DMERC) rules with respect to the usual medically necessary quantity of supplies for PAP devices.

Examples of failed CPAP include but are not limited to:
- Claustrophobia
- Inability to breathe through the nose
- Patient intolerance
- Discomfort or pain
- Patients requiring high pressures of CPAP (greater than 10 cm H2O) complaining of pressure discomfort

Coverage for the following (in the diagnosis of OSA) may depend upon the applicable health benefit plan definition of medical necessity. Many health plans administered by Blue Shield contain definitions of medical necessity which include a cost comparison component. For those plans, Blue Shield will apply medical necessity criteria. In accordance with Blue Shield's medical necessity criteria, if there are two or more medically necessary services that may be provided for an illness, injury or medical condition, Blue Shield will provide benefits based on the most cost effective service.

**Coding**

**Attended Studies**

- **95807**: Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist
- **95808**: Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist
- **95810**: Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist
- **95811**: Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist
- **95782**: Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist
- **95783**: Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist

**Unattended Studies**

- **95806**: Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (e.g., thoracoabdominal movement) (Note that this CPT code is identical to 95807 except that the study is not monitored)
- **95800**: Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time
- **95801**: Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (e.g., by airflow or peripheral arterial tone)
95800 and 95801 differ from 95806 in the description of a single respiratory sensor (either air flow or peripheral arterial tone) instead of the standard configuration of both respiratory effort and respiratory airflow (ventilation).

Use of overnight oximetry alone would be indicated by the following CPT code:
- **94762**: Noninvasive ear or pulse oximetry for oxygen saturation; by continuous overnight monitoring (separate procedure)

**HCPCS Codes**

There is 1 HCPCS code identifying a CPAP device, E0601, and 2 HCPCS codes for bilevel positive airway pressure (BiPAP) devices, E0470 and E0471. HCPCS codes do not distinguish among fixed CPAP or BiPAP devices and auto-adjusting CPAP devices.

Medicare created the following G codes to facilitate their national coverage decision:
- **G0398**: Home sleep study test (HST) with type II portable monitor, unattended; minimum of 7 channels: EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort and oxygen saturation
- **G0399**: Home sleep study test (HST) with type III portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate and 1 oxygen saturation
- **G0400**: Home sleep study test (HST) with type IV portable monitor, unattended; minimum of 3 channels

The following HCPCS code is for the oral interface used with devices such as the Winx system:
- **A7047**: Oral interface used with respiratory suction pump, each

The system would be reported using code E0600 - Respiratory Suction Pump, Home Model, Portable or Stationary, Electric and code A7002 - Tubing, Used with Suction Pump, Each.

Refer to Blue Shield of California Medical Policy: Home Apnea Monitors for further information on neonatal home cardiorespiratory monitoring (CPT codes 94772-94777). These codes are not appropriate for the diagnosis of sleep apnea in children.

### Description

Obstructive sleep apnea (OSA) syndrome is characterized by repetitive episodes of upper airway obstruction due to the collapse of the upper airway during sleep. Polysomnography and portable sleep monitoring with type 3 monitors are established methods for diagnosing OSA. Other proposed methods of diagnosing OSA include limited channel home sleep monitors. Conventional medical management of OSA includes weight loss, avoidance of stimulants, body position adjustment, oral appliances, and use of continuous positive airway pressure (CPAP) during sleep. Novel treatments include nasal expiratory positive airway pressure (EPAP) and oral pressure therapy.

### Related Policies

- Actigraphy
- Home Cardiorespiratory Monitoring
- Polysomnography for Non-Respiratory Sleep Disorders
- Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome

### Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the
time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates [e.g., Federal Employee Program (FEP)] prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

**Regulatory Status**

A variety of oral appliances have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for treatment of snoring and mild-to-moderate sleep apnea, including the Narval™ CC, Lamberg Sleep Well Smartrusion, 1st Snoring Appliance, Full Breath Sleep Appliance, PM Positioner, Snorenti, Snorex, Osap, Desra, Elastomeric Sleep Appliance, Snoremaster Snore Remedy, Snore-no-More, Napa, Snoar™ Open Airway Appliance, and The Equalizer Airway Device. FDA product code: LQZ

In 2014, the mRNA Appliance® (BioModeling Solutions, Beaverton, OH) was cleared for marketing by the FDA through the 510(k) process (K130067) for the treatment of snoring and mild-to-moderate OSA. FDA product code: LRK.

Various continuous positive airway pressure devices have been cleared by the FDA through the 510(k) process since 1977. Bilevel positive airway pressure devices were first cleared for marketing in 1996. FDA product codes: BZD, MNT.

In 2010, a nasal expiratory resistance valve (Provent®, Ventus Medical) was cleared for marketing by the FDA through the 510(k) process for the treatment of OSA. The Winx™ system received marketing clearance in 2012. FDA product code: OHP, OZR.

**Rationale**

**Background**

**Obstructive Sleep Apnea**

Obstructive sleep apnea (OSA) syndrome is characterized by repetitive episodes of upper airway obstruction due to the collapse of the upper airway during sleep. This causes a drop in blood oxygenation and a brief arousal, and can occur as frequently as every minute throughout the night. The most common signs and symptoms in adults are snoring, excessive daytime sleepiness, and hypertension. Excessive daytime sleepiness may be subjective, and is assessed by questionnaires such as the Epworth Sleepiness Scale, a short self-administered questionnaire that asks patients how likely they are to fall asleep in different scenarios such as watching TV, sitting quietly in a car, or sitting and talking to someone. Daytime sleepiness is uncommon in young children with OSA. Symptoms in children may include disturbed sleep and daytime neurobehavioral problems. In otherwise healthy children, OSA is usually associated with adenotonsillar hypertrophy and/or obesity.

A hallmark sign of OSA is snoring. The snoring abruptly ceases during the apneic episodes and during the brief period of patient arousal and then resumes when the patient again falls asleep. Upper airway resistance syndrome (a variant of OSA characterized by a partial collapse of the airway, resulting in increased resistance to airflow. The increased respiratory effort is associated with multiple sleep fragmentations, as measured by very short alpha electroencephalographic (EEG) arousals ("respiratory event-related arousals" [RERAs]). The sleep fragmentation associated with repeated sleep disruption can lead to impairment of daytime activity. Adults with OSA-associated daytime somnolence are thought to be at higher risk for collisions involving motorized vehicles (i.e., cars, trucks, heavy equipment), while OSA in children may result in neurocognitive impairment and behavioral problems.
OSA can also affect the cardiovascular and pulmonary systems. For example, apnea leads to periods of hypoxemia, alveolar hypoventilation, hypercapnia, and acidosis. This in turn can cause systemic hypertension, cardiac arrhythmias, pulmonary hypertension, and cor pulmonale. Systemic hypertension is common in patients with OSA. Severe OSA is also associated with decreased survival, presumably related to severe hypoxemia, hypertension, or an increase in automobile collisions related to daytime sleepiness. It is estimated that about 7% of adults have moderate or severe OSA, 20% have mild OSA, and the referral population of OSA patients represents a small proportion of patients who have clinically significant and treatable disease.¹

**Diagnosis**

The criterion standard diagnostic test for sleep disorders is a polysomnogram performed in a sleep laboratory.² A standard polysomnogram includes EEG, submental electromyogram, and electro-oculogram (to detect rapid eye movement sleep) for sleep staging. Polysomnography (PSG) also typically includes electrocardiography and monitoring of respiratory airflow, effort, snoring, oxygen desaturation, and sleep position. An attended study ensures that the electrodes and sensors are functioning adequately and do not dislodge during the night. In addition, an attendant is able to identify severe OSA in the first part of the night and titrate continuous positive airway pressure (CPAP) in the second part of the night, commonly known as a "split-night" study. If successful, this strategy eliminates the need for an additional PSG for CPAP titration. Auto-adjusting positive airway pressure (APAP) may also be used to determine the most effective pressure.

Typically, the evaluation of OSA includes sleep staging to assess arousals from sleep and determination of the frequency of apneas and hypopneas. In adults, apnea is defined as a drop in the peak signal excursion (airflow) by 90% or more of pre-event baseline for at least 10 seconds.³ Hypopnea in adults is scored when the peak signal excursions drop by at least 30% of pre-event baseline for at least 10 seconds in association with either at least 3% arterial oxygen desaturation or an arousal. The Apnea/Hypopnea Index (AHI) and the Respiratory Disturbance Index (RDI) are 2 instruments that report on respiratory events during sleep. The AHI is defined as the total number of events per hour of sleep. RDI may be defined as the number of apneas, hypopneas, and RERAs per hour of sleep. When sleep onset and offset are unknown (e.g., in home sleep studies), the Respiratory Event Index may be calculated based on the number of apneas and hypopneas per hour of recording time. A diagnosis of OSA is accepted when an adult has an AHI greater than 5 events per hour and symptoms of excessive daytime sleepiness or unexplained hypertension. An AHI of 15 or more events per hour is typically considered moderate OSA, while an AHI greater than 30 is considered severe OSA.

Due to faster respiratory rates in children, pediatric scoring criteria define an apnea as 2 or more missed breaths, regardless of its duration in seconds. An apnea is scored when peak signal excursions (airflow) drop by at least 90% of pre-event baseline and the event meets duration and respiratory effort criteria for an obstructive, mixed, or central apnea.³ A hypopnea is scored in children when the peak signal excursions drop is at least 30% of pre-event baseline for at least the duration of 2 breaths in association with either a 3% or greater oxygen desaturation or an arousal. In pediatric patients, an AHI greater than 1.5 events per hour is considered abnormal, and an AHI of 10 or more may be considered severe. Although there is poor correlation between AHI and OSA symptoms, an increase in mortality is associated with an AHI of 15 or more events per hour in adults. Mortality has not been shown to be increased in adults with an AHI between 5 (considered normal) and 15 events per hour.

A variety of devices have been developed specifically to evaluate OSA at home. They range from portable full PSG systems to single-channel oximeters. Available devices evaluate different parameters, which may include oximetry, respiratory and cardiac monitoring, and sleep/wake activity, but the majority of portable monitors do not record EEG activity.
Medical Management

Medical management of OSA in adults may include weight loss, avoidance of stimulants, body position adjustment, oral appliances, and use of various types of positive airway pressure therapy (i.e., fixed CPAP, bilevel positive airway pressure [BiPAP], or APAP) during sleep.

CPAP involves the administration of air, usually through the nose, by an external device at a fixed pressure to maintain the patency of the upper airway. BiPAP is similar to CPAP, but these devices are capable of generating 2 adjustable pressure levels. APAP adjusts the level of pressure based on the level of resistance and thus administers a lower mean level of positive pressure during the night. It has been hypothesized that both BiPAP and APAP are more comfortable for the patient and thus might improve patient compliance or acceptance.

Oral appliances can be broadly categorized as mandibular advancing or positioning devices or tongue-retaining devices. Oral appliances can either be “off the shelf” or customized for the patient by a dental laboratory or similar provider.

The Daytime Nighttime Appliance (DNA Appliance, Biomodeling Solutions) and the mandibular Repositioning Nighttime Appliance (mRNA Appliance, Biomodeling Solutions) are customized palate and mandible expanding devices. In addition to the upper-jaw device that is common to both the DNA Appliance and the mRNA Appliance (worn both during the day and night), the mRNA Appliance moves the mandible forward and is worn during sleep. The DNA Appliance and mRNA Appliance systems use 3-dimensional axial springs which are proposed to expand the upper and lower jaw and airway gradually to treat and eliminate mild-to-moderate OSA eventually.

Other devices being marketed for the treatment of OSA are Provent and Winx. Provent is a single-use nasal expiratory resistance valve device containing valves inserted into the nostrils and secured with adhesive. The Winx system uses oral pressure therapy to treat OSA. Oral pressure therapy provides light negative pressure to the oral cavity by using a flexible mouthpiece connected to a bedside console that delivers negative pressure. This device is proposed to increase the size of the retropalatal airway by pulling the soft palate forward and stabilizing the base of the tongue.

Surgical management of OSA (i.e., adenotonsillectomy, uvulopalatopharyngoplasty, orthognathic surgery) is discussed in Blue Shield of California Medical Policy: Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome.

Literature Review

Suspected Obstructive Sleep Apnea

Multichannel Home Sleep Testing

In 2011, the Agency for Healthcare Research and Quality (AHRQ) conducted a comparative effectiveness review (CER) on the diagnosis and treatment of obstructive sleep apnea (OSA) in adults. The CER found strong evidence that an Apnea/Hypopnea Index (AHI) greater than 30 events per hour is an independent predictor of all-cause mortality, with low or insufficient evidence for an association between AHI and other clinical outcomes. The CER found moderate evidence that type 3 and 4 monitors may have the ability to accurately predict AHI suggestive of OSA and that type 3 monitors perform better than type 4 monitors at AHI cutoffs of 5, 10, and 15 events per hour.

Section Summary: Multichannel Home Sleep Testing

Based on this evidence and society guidelines, portable monitoring with a minimum of 4 recording channels (including oxygen saturation, respiratory movements, airflow, and electrocardiogram or heart rate) for the diagnosis of OSA in adults who are at high risk for OSA improves outcomes, when clinical evaluation and follow-up are conducted by a medical professional experienced in the diagnosis and treatment of sleep disorders.
Limited Channel Home Sleep Testing
Use of Auto-Adjusting Positive Airway Pressure for Diagnosis and Treatment Supervised by a Sleep Specialist

Mulgrew et al (2007) published a randomized validation study of the diagnosis and management of OSA with a single-channel monitor followed by auto-adjusting positive airway pressure (APAP). They developed a diagnostic algorithm that had a 94% positive predictive value for moderate-to-severe OSA assessed by polysomnography (PSG). Patients who passed the screening (n=68) were randomized to attended in-laboratory PSG with CPAP titration or to home monitoring with a portable APAP unit. No difference was observed between lab-PSG and home-managed patients for any of the outcome measures. Senn et al (2006) assessed whether an empirical approach, using a 2-week trial of APAP, could effectively diagnose OSA. Patients (N=76) were included in the study if they had been referred by primary care physicians for evaluation of suspected OSA, were habitual snorers, complained of daytime sleepiness, and had an ESS score of 8 or greater (mean, 13.6). At the end of the 2-week trial, patients were asked to rate the perceived effect of treatment and to indicate whether they had used CPAP for more than 2 hours per night and were willing to continue treatment. Patients without a clear benefit of CPAP received further evaluation including clinical assessment and PSG. Compared with PSG, patient responses showed a sensitivity of 80%, a specificity of 97%, a positive predictive value of 97%, and a negative predictive value of 78.

Berry et al (2008) randomized 106 patients referred for a sleep study for suspected OSA at a local Veterans Administration center to portable monitoring followed by APAP or to PSG for diagnosis and treatment. Patients were screened with a detailed sleep and medical history questionnaire, and patients on α-blockers or not in sinus rhythm were excluded due to the type of portable monitoring device used (Watch-PAT 100). Of the 53 patients randomized to PSG, 6 (11%) did not have PSG-defined OSA; in the portable monitoring arm, 4 (8%) of 53 patients were found not to have OSA. Treatment outcomes were similar in both groups, with a 7-point improvement in ESS score, 3-point improvement in the Functional Outcomes of Sleep Questionnaire score, and a machine estimate of residual AHI of 3.5 events per hour in the portable monitoring APAP group and 5.3 in the PSG group.

Peripheral Arterial Tone

In 2009, the Centers for Medicare & Medicaid issued a coverage decision to accept use of a sleep testing device that included actigraphy, oximetry, and peripheral arterial tone to aid the diagnosis of OSA in beneficiaries with signs and symptoms indicative of OSA. (See the Medicare National Coverage section below.) A separate 2009 literature review of this technology identified a 2009 review of use of peripheral arterial tone for detecting sleep-disordered breathing. This review included the critical evaluation of studies comparing the Watch-PAT with laboratory-based PSG. Studies that included appropriate study populations (patients referred for evaluation of OSA or following CPAP treatment) are described below.

Pittman et al (2006) evaluated residual OSA in 70 patients who had self-reported adherence to CPAP for at least 3 months. Exclusion criteria for the study included use of α-adrenergic blockers. Compared with concurrently recorded PSG, the area under the curve receiver operator characteristic curve analysis for Respiratory Disturbance Index (RDI) greater than 15 events per hour was 0.95 (85% sensitivity, 90% specificity). Specificity decreased dramatically at lower cutoffs (67% for RDI >10 events per hour, 47% for RDI >5 events per hour). Another small study (2007) of 37 consecutive patients referred to a sleep center for OSA reported a high correlation between PSG and concurrently recorded Watch-PAT RDI (r=0.93). (Correlation coefficients are not considered as meaningful as estimates of sensitivity and specificity.) Sensitivities for an AHI greater than 5, 15, and 35 events per hour in this study were 94%, 96%, and 83% respectively. Specificity was reported at 80%, 79%, and 72%, respectively, for these thresholds.
Penzel et al (2004) assessed the specificity of the Watch-PAT device in a small independently conducted study of 21 patients with suspected sleep apnea. The study found that, for 16 of the 17 subjects with adequate recordings, the number of Watch-PAT events was greater than the number of respiratory events. The device was found to have reasonable reliability and to be very sensitive to arousal, although because arousals are not unique to apnea events, the study concluded that the specificity of the Watch-PAT was limited.

There is also uncertainty about the clinical utility of the indirect measure of peripheral arterial tone compared to measuring airflow and respiratory effort directly. In 2004, Pittman et al noted other potential disadvantages of the Watch-PAT, including its inability to differentiate between the type of respiratory event (e.g., obstructive, central, mixed, or hypopnea) or to identify body position, and its susceptibility to artifact from arrhythmias. It is noteworthy that the American Academy of Sleep Medicine (AASM) has not changed its 2007 guidelines, recommending that portable monitors should minimally record airflow, respiratory effort, and blood oxygenation, using biosensors conventionally used for in-laboratory PSG. At this time, evidence does not support a change in the sensors required for portable monitoring.

Apnea Risk Evaluation System
In 2008, Ayappa et al reported on a validation study of a small apnea monitor that is self-applied to the forehead. The device measures blood oxygen saturation and pulse rate, airflow, snoring levels, head movement, and head position. The study enrolled 80 individuals with a high likelihood of OSA and 22 with a low risk of OSA; results of simultaneous Apnea Risk Evaluation System (ARES) recording and PSG were available for 92 individuals. When healthy subjects were excluded from analysis, sensitivity (91%) and specificity (92%) were relatively high, for an AHI of 15 or more events per hour, but dropped considerably with an AHI between 5 and 15 (sensitivity, 97%; specificity, 78%). Five percent of the subjects could not tolerate the device and were excluded from analysis.

Monitoring of APAP use by daily transmission to a web-based database and review by a research coordinator has been shown to improve compliance to positive airway pressure therapy (191 min/d vs 105 min/d). For the telemedicine arm of this randomized trial, the research coordinator reviewed the transmitted data daily and contacted the patient if any of the following were present: mask leak greater than 40 L/min for more than 30% of the night, less than 4 hours of use for 2 consecutive nights, machine-measured AHI of more than 10 events per hour, and 90th percentile of pressure greater than 16 cm H2O. Evaluation by their physician sleep specialist after 3 months of therapy showed a similar modest decrease in AHI for the 2 groups (1.6 for telemedicine, 0.7 for controls).

Section Summary: Limited Channel Home Sleep Testing
The evidence for limited channel home sleep testing (includes type 4 monitors and WatchPAT) in patients who have OSA consists of studies on diagnostic accuracy. A number of questions remain about the ability of this home sleep testing to detect clinically significant OSA without sensors for heart rate, respiratory effort, airflow, and oxygen saturation.

Diagnosed Obstructive Sleep Apnea
Positive Airway Pressure Devices
The 2011 AHRQ CER concluded that the strength of evidence for continuous positive airway pressure (CPAP) for OSA was moderate based on the large magnitude of effect on the intermediate outcomes of the AHI, Epworth Sleepiness Scale (ESS), and arousal index, even though there was weak evidence demonstrating an effect of CPAP on clinical outcomes. In addition, the review found moderate evidence that APAP and fixed-pressure CPAP result in similar levels of compliance (hours used per night) and treatment effects for patients with OSA. There was moderate evidence that CPAP is superior to mandibular advancement devices in improving sleep study measures.
Evidence-based guidelines from AASM concluded that CPAP and APAP devices have similar outcomes in terms of AHI, oxygen saturation, and arousals.17-20 As indicated in the CER, increased compliance with APAP devices has not been well-documented in clinical trials.21-23 Thus, the issues associated with APAP are similar to those for bilevel positive airway pressure.

The 2016 SAVE randomized controlled trial (RCT) found no benefit of CPAP on the primary composite outcome of death or hospitalization for cardiovascular events in 2717 adults with moderate-to-severe OSA and cardiovascular disease.24 With a mean duration of adherence to CPAP therapy of 3.3 hours per night, CPAP significantly reduced daytime sleepiness (adjusted difference in ESS score, -2.5; 95% confidence interval [CI], -2.8 to -2.2; p < 0.001) and improved health-related quality of life and mood. An improvement in postoperative outcomes with CPAP was suggested in a 2014 matched comparison of patients with OSA who had been diagnosed prior to surgery (2640 surgeries), those not diagnosed until up to 5 years after surgery (1571 surgeries), and 16,277 surgeries for patients without a diagnosis of OSA out of 21 years of available data.25 In multivariate analysis, the risk of respiratory complications was increased for both diagnosed and undiagnosed OSA patients compared to controls (odds ratio, 2.08; p < 0.001). The risk of cardiovascular complications, primarily cardiac arrest and shock, was higher in OSA patients not diagnosed until after surgery (relative risk [RR], 2.20; 95% CI, 1.16 to 4.17; p = 0.02), but not in those diagnosed prior to surgery (RR = 0.75; 95% CI, 0.43 to 1.28; p = 0.29); the difference between groups was significant (p = 0.009). There was a significant trend toward a higher risk with increasing OSA severity. Study limitations included the inability to determine whether CPAP was used perioperatively, and, because body mass index could not be determined, potential confounding from the close association between obesity and OSA.

A systematic review of the evidence on the treatment of OSA with oral appliance therapy was performed for a 2015 update of practice guidelines by AASM and the American Academy of Dental Sleep Medicine.26 Meta-analysis showed that oral appliances reduced the AHI, arousal index, and oxygen desaturation index, and increase oxygen saturation. However, oral appliances had no significant effect on sleep architecture or sleep efficiency. Meta-analysis found CPAP to be more effective than oral appliances in reducing the AHI, arousal index, and oxygen desaturation index, and in improving oxygen desaturation, supporting the use of CPAP as a first-line therapy for treating OSA.

**Subsection Summary: Positive Airway Pressure Devices**

Positive airway pressure devices are accepted therapies for OSA. Studies suggest that both CPAP and APAP are associated with improvements in sleep architecture.

**Mandibular Advancement Device**

In 2017, Johal et al reported on a randomized crossover trial of ready-made versus custom-made mandibular repositioning devices.27 Twenty-five patients with mild-to-moderate OSA (mean AHI, 13.3 events/h; range, 10.9-25 events/h) were randomized to a 3-month trial of a ready-made or a custom-made device, with a 2-week washout between treatments. An overnight home sleep study was performed at baseline and on the last night of the 3-month trial period. Patients used the custom-made device for more nights per week (7 vs 3, p = 0.004) and hours per night (5 vs 3, p = 0.006) than the ready-made device. Treatment response (AHI < 5 events/h) was obtained in 64% of patients during use of the custom-made device phase compared to a 24% response rate with the ready-made device (p < 0.001). Treatment failure (<50% reduction in AHI) was more frequent with the ready-made device (36%) than with the custom device (4%), while an ESS score of at least 10 was more frequent during the ready-made phase (66%) compared to the custom made phase (33%). An improvement in quality of life was observed only during the custom-made device phase.

In the 2011 AHRQ CER on the diagnosis and treatment of OSA in adults, the strength of the evidence that mandibular advancement devices improve sleep apnea signs and symptoms was rated moderate.4
Novel Obstructive Sleep Apnea Treatments

Palate and Mandible Expansion

In 2016, Singh et al reported on a series of 15 consecutive patients with severe sleep apnea who were treated with a DNA Appliance or mRNA Appliance. All patients had failed to comply with CPAP. Pre- and posttreatment AHI was assessed in a home sleep study without the oral appliance. AHI decreased from a mean 45.9 events per hour to 16.5 (p<0.01) after a mean 9.7 months of treatment. In a 2017 study, Singh and Cress reported on a series of 19 patients who had mild-to-moderate sleep apnea who were treated with a DNA or mRNA Appliance. Only patients who complied with oral appliance wear were included in the study. The mean AHI was reduced from 12.85 to 6.2 events per hour (p<0.001) without the appliance while the oxygen saturation index improved from 6.3% to 2.6% (p<0.001). Limitations of these studies included the use of a home sleep study rather than the more accurate laboratory PSG, uncertain blinding of the physician evaluating the sleep study, the small number of patients studied, the lack of intention-to-treat analysis, and the lack of long-term follow-up.

Positive Airway Pressure-NAP

In 2008, Krakow et al reported use of a daytime abbreviated sleep study to acclimate patients with complex insomnia to PAP. Patients had been referred by psychiatrists or primary care physicians for unspecified insomnia conditions, insomnia due to a mental disorder, or hypnotic dependence. Nearly all patients had anxiety, fear, and/or resistance regarding PAP therapy or the diagnosis of OSA. Thirty-nine patients who would not complete a titration protocol (full-night or split-night) were offered a daytime procedure (PAP-NAP) prior to night-time titration. The PAP-NAP protocol had 5 components: pretest instructions to maximize chances for daytime napping; introduction of PAP therapy addressing barriers to use; type 3 monitoring hookup (10 channels without electroencephalography leads); PAP therapy during 1 to 2 hours in bed in which the patient had the opportunity to fall asleep with the mask in place; and posttest follow-up. Thirty-five of 39 nap-tested patients subsequently scheduled and completed an overnight titration or split-night study with full PSG. The effect of the PAP-NAP intervention on compliance was compared to historical controls (n=38) with insomnia, mental health conditions, and OSA with resistance to CPAP who completed titration. A prescription for PAP therapy was filled by 85% of the PAP-NAP group compared with 35% of controls. Regular use during a 30-day period was recorded by the PAP device in 67% of the intervention group than in 23% of controls. Adherence, defined as at least 5 days a week with an average of at least 4 hours a day, was 56% in the PAP-NAP group and 17% in controls.

Nasal Expiratory Positive Airway Pressure

Evidence includes a moderately sized RCT and a systematic review on the Provent device. In 2011, Berry et al reported an industry-sponsored multicenter, double-blind, randomized sham-controlled trial of nasal expiratory positive airway pressure (EPAP). Two hundred fifty patients with OSA and an AHI of 10 or more events per hour were randomized to nasal EPAP (n=127) or to a sham device (n=123) for 3 months. PSG was performed on 2 nights (device-on, device off, in a random order) at week 1 (92% follow-up) and after 3 months of treatment (78% follow-up). EPAP reduced median AHI from 13.8 to 5.0 events per hour (-52.7%) at week 1 and from 14.4 to 5.6 events per hour (-42.7%) at 3 months. This reduction in AHI in the treatment group was significantly greater than in the sham group (-7.3% at week 1, -10.1% at 3 months). Over 3 months, the decrease in ESS score was statistically greater in the EPAP group (from 9.9 to 7.2) than in the sham group (from 9.6 to 8.3), although the clinical significance of a 1-point difference in ESS score is unclear. Treatment success and oxygenation data were presented only for the 58% of per-protocol patients who had an AHI of 5 or more events per hour on the device-off PSG night. The oxygenation results (oxygenation desaturation index and percent of total sleep time with oxygen saturation <90%) showed small but statistically significant decreases at 1 week and 3 months. Treatment success, defined as a 50% or greater reduction in the AHI or an AHI reduction to less than 10 events per hour (if device-off AHI was ≥10 events per hour), was greater in the EPAP group at 1 week (62% vs 27.2%) and at 3 months (50.7% vs 22.4%). Device-related adverse events were reported by 45% of patients in the EPAP group and by 34% of
patients in the sham group, with 7% of patients in the EPAP group discontinuing due to adverse events. Overall, the validity of these results was limited by the high dropout rate, and the clinical significance of the results is uncertain.

An open-label extension of the 2011 randomized study by Berry evaluated 12-month safety and durability of the treatment response in patients who had an initially favorable response to EPAP. Included were 41 (32%) of the 127 patients in the EPAP arm of the study who used the device for an average of at least 4 hours per night on at least 5 nights a week during months 1 and 2 and had at least a 50% reduction in AHI, or reduction to less than 10 events per hour, compared to the device-off PSG. Of the 51 (40%) of 127 eligible patients, 41 enrolled in the extension study, and 34 (27%) of 127 were still using the EPAP device at the end of 12 months. Median AHI was reduced from 15.7 to 4.7 events per hour; the percentage of patients who met criteria for success was not reported. The arousal index was modestly decreased (from 23.9 to 19.0). Over 12 months of treatment, the ESS score decreased from 11.1 to 6.0. The median percentage of reported nights used (entire night) was 89.3%. Device-related adverse events were reported by 42% of patients, most frequently difficulty exhaling, nasal discomfort, dry mouth, headache, and insomnia. This open-label extension study was limited by its inclusion only of responders and by the potential for a placebo effect on the ESS score. However, the data suggested that some patients may have responded to this device, and the patient compliance data might indicate a positive effect on daytime sleepiness that leads to continued use of the device in about 25% of patients. Additional controlled studies are needed to distinguish between these alternatives.

A 2015 systematic review identified 18 studies (total N=920 patients) that had data on pre- and postnasal EPAP. Study designs included 10 conference papers and 8 publications (case series, cohort studies, RCTs). Of patients included in the meta-analysis (n=345 patients) AHI decreased from 27.32 to 12.78 events per hour (p<0.001). For 359 patients, ESS score modestly improved from 9.9 to 7.4 (p<0.001). Data from the Berry RCT (described above) were not included in this meta-analysis because mean data were not reported. Response to nasal EPAP was variable and inconsistent, and there were no clear characteristics (demographic factors, medical history, and/or physical exam finding) that predicted a favorable response.

Kureshi et al (2014) reported on a small (N=14) double-blind, pilot, crossover RCT of EPAP in children to evaluate efficacy and compliance with this new treatment. PSG with EPAP or a placebo device showed a significant mean improvement in Obstructive Apnea Index with EPAP (index of 0.6 vs 4.2, p=0.01), but responses varied (3 did not improve, 2 worsened). No other measures were statistically significant in this trial. For responders who used the devices at home for 30 days, adherence was 83% of nights. ESS scores improved from 11 to 7 (p=0.031) and Obstructive Sleep Apnea–18 questionnaire scores improved from 50 to 39 (p=0.028). Other outcome measures did not improve significantly.

**Oral Pressure Therapy**

No full-length, peer-reviewed studies on oral pressure therapy were identified in the published literature. Therefore, it is not possible to evaluate the efficacy of this treatment based on scientific evidence.

**Section Summary: Novel OSA Treatments**

The evidence on palate and mandible expansion devices includes a few small cohort studies. Further study with well-designed trials is needed to evaluate this treatment.

The evidence on EPAP devices in patients with OSA has been reported in several prospective case series, 1 industry-sponsored RCT, and a systematic review that did not include the RCT. The main finding of the RCT was a decrease in AHI with a minor impact on oxygenation and ESS score.

One comparative trial with historical controls used a PAP-NAP study of patients with complex insomnia who are resistant to CPAP titration or use. This single study of PAP-NAP does not provide
sufficient evidence to form conclusions on the efficacy of this approach in improving compliance with CPAP. The patient population was highly selected and the behavioral intervention may be dependent on the specific clinicians providing treatment. In addition, historical controls were used, and they were not well-matched to the study population. For these reasons, the internal validity and generalizability of the results are uncertain.

Summary of Evidence
For individuals who have suspected obstructive sleep apnea (OSA) who receive home sleep testing with at least 4 recording channels, the evidence includes randomized controlled trials (RCTs). Relevant outcomes are test accuracy, symptoms, functional outcomes, and resource utilization. RCTs have reported that home sleep testing with type 3 monitors (those with ≥4 recording channels) is noninferior to testing in the sleep lab for adults with a high pretest probability of OSA and absence of comorbid conditions as determined by clinical evaluation. A positive portable monitoring study with channels that include arterial oxygen saturation, airflow, and respiratory effort has a high positive predictive value for OSA and can be used as the basis for a continuous positive airway pressure (CPAP) trial to determine efficacy of treatment. A negative portable monitoring study cannot be used to rule out OSA. Patients who have a negative result from portable monitoring or have a positive study but do not respond to CPAP should undergo further evaluation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have suspected OSA who receive limited channel home sleep testing, the evidence includes studies on diagnostic accuracy. Relevant outcomes are test accuracy, symptoms, functional outcomes, and resource utilization. The ability to detect clinically significant OSA without sensors for heart rate, respiratory effort, airflow, and oxygen saturation lacks support in the literature. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have OSA who receive positive airway pressure or mandibular advancement devices, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, and quality of life. Conventional medical management of OSA includes weight loss, avoidance of stimulants, body position adjustment, oral appliances, and use of CPAP during sleep. A diagnostic sleep study may be followed by a trial of auto-adjusting positive airway pressure to evaluate efficacy and adjust pressure. Auto-adjusting positive airway pressure or bilevel positive airway pressure may also be indicated if the patient is intolerant of CPAP. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have OSA who receive novel OSA treatments (e.g., expiratory positive airway pressure, oral pressure therapy, palate, and mandible expansion), the evidence includes 1 RCT and a meta-analysis of case series. Relevant outcomes are symptoms, functional outcomes, and quality of life. The evidence on palate and mandible expansion devices includes a few small series. Further study with well-designed trials is needed to evaluate this treatment. The evidence on expiratory positive airway pressure devices in patients with OSA has been reported in prospective case series, 1 industry-sponsored RCT, and a systematic review that did not include the RCT. The main finding of the RCT was a decrease in the Apnea/Hypopnea Index, with minor impact on oxygenation, and a decrease in Epworth Sleepiness Scale score. One comparative trial with historical controls used a positive airway pressure nap (PAP-NAP) to study patients with complex insomnia resistant to CPAP titration or use. Additional study is needed to evaluate with greater certainty the efficacy of this intervention. No evidence was identified on use of the oral therapy device or palate and mandible expansion devices. The evidence is insufficient to determine the effects of the technology on health outcomes.
Supplemental Information
Clinical Input from Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2014 Input
In response to requests from Blue Cross Blue Shield Association, input was received from 7 physician specialty societies (8 reviewers) and 4 academic medical centers (6 reviewers) in 2014. Input focused on routine screening of patients scheduled to undergo bariatric surgery. There was consensus that routine screening is considered medically necessary in this population due to the high prevalence of obstructive sleep apnea (OSA) in patients with a body mass index greater than 40 kg/m², combined with the increased rate of perioperative complications in patients with OSA. Input was mixed on whether the use of portable home sleep testing was appropriate for patients scheduled for bariatric surgery. Concerns were raised about the high prevalence of obesity hypoventilation syndrome in this population, which is a contraindication to home sleep testing. Other reviewers considered home sleep testing to be appropriate in patients scheduled for bariatric surgery, with the caveat that obesity hypoventilation syndrome should be ruled out prior to home sleep testing.

2010 Input
In response to requests from Blue Cross Blue Shield Association, input was received from 1 physician specialty society and 6 academic medical centers (8 reviewers) in 2010. Input focused on the sensors required for unattended home sleep studies and on diagnosis and treatment of OSA in children. In general, reviewers supported the requirement that home monitors measure 4 parameters, including respiratory effort, airflow, and oxygen saturation, and that their use be restricted to adults. Some exceptions were noted for specific situations. The 2010 update included recommendations from reviewers on indications specific to pediatric patients.

2009 Input
In response to requests from Blue Cross Blue Shield Association, input was received from 5 physician specialty societies (6 reviewers) and 3 academic medical centers in 2009. Professional society guidelines and position statements were also reviewed. In general, input supported the use of polysomnography, portable sleep monitoring tests, multiple sleep latency test, and continuous positive airway pressure for adults as described in the policy. The update included the reviewers’ recommendations for clarifications and modifications to the policy statements.

Practice Guidelines and Position Statements
American Academy of Sleep Medicine
In 1997 the American Sleep Disorders Association (now the American Academy of Sleep Medicine [AASM]) published practice parameters for polysomnography (PSG) and related procedures; they were most recently updated in 2005. The guidelines suggested that patients had a 70% likelihood of having an Apnea/Hypopnea Index (AHI) of at least 10 events per hour if all of the following were present: habitual snoring, excessive daytime sleepiness, a body mass index greater than 35 kg/m², and observed apnea.

In 2017, AASM published clinical practice guidelines on diagnostic testing for adult obstructive sleep apnea (OSA). AASM provided the following recommendations (see Table 1).

Table 1. Summary of Recommendations
<table>
<thead>
<tr>
<th>Recommendation Statement</th>
<th>SOR</th>
<th>QOE</th>
<th>Benefits vs Harms</th>
</tr>
</thead>
<tbody>
<tr>
<td>We recommend that clinical tools, questionnaires, and prediction algorithms not be used to diagnose OSA in adults, in the absence of PSG or HSAT</td>
<td>Strong</td>
<td>Moderate</td>
<td>High certainty that harms outweigh benefits</td>
</tr>
<tr>
<td>Recommendation Statement</td>
<td>SOR</td>
<td>QOE</td>
<td>Benefits vs Harms</td>
</tr>
<tr>
<td>--------------------------</td>
<td>------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>We recommend that PSG, or HSAT with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA.</td>
<td>Strong</td>
<td>Moderate</td>
<td>High certainty that benefits outweigh harms</td>
</tr>
<tr>
<td>We recommend that if a single HSAT is negative, inconclusive, or technically inadequate, PSG be performed for the diagnosis of OSA.</td>
<td>Strong</td>
<td>Low</td>
<td>High certainty that benefits outweigh harms</td>
</tr>
<tr>
<td>We recommend that PSG, rather than home sleep testing, be used for patients with significant cardiorespiratory disorder, potential respiratory muscle weakness, awake or suspected sleep hypoventilation, chronic opioid medication use, history of stroke or severe insomnia.</td>
<td>Strong</td>
<td>Very low</td>
<td>High certainty that benefits outweigh harms</td>
</tr>
<tr>
<td>We suggest that, if clinically appropriate, a split-night diagnostic protocol, rather than a full-night diagnostic protocol for PSG be used for the diagnosis of OSA.</td>
<td>Weak</td>
<td>Low</td>
<td>Low certainty that benefits outweigh harms</td>
</tr>
<tr>
<td>We suggest that when the initial PSG is negative, and there is still clinical suspicion for OSA, a second PSG be considered for the diagnosis of OSA.</td>
<td>Weak</td>
<td>Very low</td>
<td>Low certainty that benefits outweigh harms</td>
</tr>
</tbody>
</table>

HSAT: home sleep apnea testing; OSA: obstructive sleep apnea; PSG: polysomnography; QOE: quality of evidence; SOR: strength of recommendation.

AASM also issued guidelines in 2009 on the evaluation, management, and long-term care of adults with OSA. The levels of recommendation are “standard” (generally accepted patient-care strategy, with high degree of certainty; level 1 to 2 evidence), “guideline” (moderate degree of clinical certainty; Level 2 to 3 evidence), or “option” (uncertain clinical use; insufficient or inconclusive evidence).

**Diagnosis**

AASM recommended that patients who are obese, retrognathic, hypertensive, or who complain of snoring or daytime sleepiness should be assessed for presence or absence as well as severity of OSA using the following methods (standard):

- **Sleep history assessment** includes “witnessed apneas, gasping/choking at night, excessive sleepiness… total sleep amount, nocturia, morning headaches… and decreased concentration and memory.”
- **Physical assessment** includes evaluation of “respiratory, cardiovascular, and neurologic systems… signs of upper respiratory narrowing…”
- **Objective testing**, under an AASM-accredited program, and attended by trained technical personnel. The diagnosis of OSA is confirmed if the number of obstructive events (apneas, hypopneas plus respiratory event related to arousals) is greater than 15 events/hour or greater than 5 events/hour in a patient reporting any of the following: unintentional sleep episodes during wakefulness; daytime sleepiness, unrefreshing sleep; fatigue; insomnia; waking up breath holding, gasping, or choking; or a bed partner describing loud snoring, breathing interruptions, or both.
  - In laboratory polysomnography (standard) records “electroencephalogram … electrooculogram … chin electromyogram, airflow, oxygen saturation, respiratory effort, … and heart rate.”
  - Home testing with portable monitors should “at minimum, record airflow, respiratory effort, and blood oxygenation.”

**Treatment with positive airway pressure**

- Continuous positive airway pressure (CPAP) is indicated for patients with “moderate to severe OSA (Standard) and mild OSA (Option).”
- Bilevel positive airway pressure can be considered in “CPAP-intolerant patients” (Consensus).
- Autotitrating positive airway pressure (APAP) can be considered in “CPAP-intolerant patients” (Consensus).
Treatment with oral appliances (OA) is indicated for “patients with mild to moderate OSA, who prefer OAs to CPAP, or who do not respond to CPAP, or are not appropriate candidates for CPAP, or who fail CPAP ... (Guideline).

- Mandibular repositioning appliance covers the upper and lower teeth.
- Tongue retaining device holds the tongue in a forward position.

In 2015, AASM and the American Academy of Dental Sleep Medicine (AADSM) published guidelines on the treatment of OSA and snoring with oral appliance therapy. AASM and AADSM provided a recommendation of “standard” that sleep physicians consider prescription of oral appliances, rather than no treatment, for adults with OSA who are intolerant of continuous positive airway pressure (CPAP) therapy or prefer alternative therapy. The quality of evidence was rated as moderate. “Guideline” recommendations were provided for the use of custom, titratable appliance over noncustom oral devices, that qualified dentists provide oversight, that sleep physicians conduct follow-up sleep testing to improve or confirm treatment efficacy, and that patients return for periodic office visits with a qualified dentist and a sleep physician.

AASM published evidence-based guidelines for respiratory indications for PSG in children in 2011. “Standard” recommendations were made for the following: PSG in children should be performed and interpreted in accordance with the AASM Manual for the Scoring of Sleep and Associated Events; PSG is indicated when the clinical assessment suggested the diagnosis of OSA in children; children with mild OSA preoperatively should have clinical evaluation following adenotonsillectomy to assess for residual symptoms. If there are residual symptoms of OSA, PSG should be performed; PSG was indicated following adenotonsillectomy to assess for residual OSA in children with preoperative evidence for moderate-to-severe OSA, obesity, craniofacial anomalies that obstruct the upper airway, and neurologic disorders; PSG was indicated for positive airway pressure titration in children with OSA.

American Academy of Pediatrics

The American Academy of Pediatrics (AAP) published 2012 guidelines on the diagnosis and management of uncomplicated childhood OSA associated with adenotonsillar hypertrophy and/or obesity in an otherwise healthy child treated in the primary care setting, which updated AAP’s 2002 guidelines. AAP recommended that all children or adolescents be screened for snoring, and PSG be performed in children or adolescents with snoring and symptoms or signs of OSA as listed in the guideline. If PSG is not available, an alternative diagnostic test or referral to a specialist, may be considered (Option). The estimated prevalence rates of OSA in children or adolescents ranged from 1.2% to 5.7%. Adenotonsillectomy was recommended as the first-line treatment for patients with adenotonsillar hypertrophy, and patients should be reassessed clinically postoperatively to determine whether additional treatment is required. High-risk patients should be reevaluated with an objective test or referred to a sleep specialist. CPAP was recommended if adenotonsillectomy was not performed or if OSA persisted postoperatively. Weight loss was recommended in addition to other therapy in patients who are overweight or obese, and intranasal corticosteroids are an option for children with mild OSA in whom adenotonsillectomy is contraindicated or for mild postoperative OSA.

American College of Physicians

The 2014 guidelines on the diagnosis of OSA in adults from the American College of Physicians (ACP) recommended that clinicians target their assessment of OSA to individuals with unexplained daytime sleepiness. ACP recommended PSG for diagnostic testing in patients suspected of OSA, and portable sleep monitors in patients without serious comorbidities as an alternative to PSG when PSG is not available for diagnostic testing (weak recommendation, moderate-quality evidence). Inconclusive areas of evidence included preoperative screening for OSA, phased testing for the diagnosis of OSA, and the utility of portable monitors for diagnosis of OSA in patients with comorbid conditions.
The 2013 ACP guidelines on the management of OSA in adults recommended that all overweight and obese patients diagnosed with OSA be encouraged to lose weight (strong recommendation, low-quality evidence).42 ACP recommended CPAP as initial therapy for patients diagnosed with OSA (strong recommendation; moderate-quality evidence), and mandibular advancement devices as an alternative therapy to CPAP for patients diagnosed with OSA who prefer mandibular advancement devices or for those with adverse effects associated with CPAP (weak recommendation, low-quality evidence).

American Academy of Craniofacial Pain
The American Academy of Craniofacial Pain (AACP) published a position paper in 2013.43 It indicated that oral appliance therapy was recognized as an effective therapy for many with primary snoring and mild-to-moderate OSA, as well as those with more severe OSA who cannot tolerate PAP therapies, but that oral appliance therapy has the potential to cause adverse effects, including temporomandibular joint pain and dysfunction. The Academy recommended that dentists engaged in, or who want to engage in, the assessment and management of patients with snoring and OSA using mandibular advancement oral appliances should be properly trained and experienced in the assessment, diagnosis and management of temporomandibular joint and craniofacial pain.

American Society of Metabolic and Bariatric Surgery
The American Society of Metabolic and Bariatric Surgery (ASMBS) published guidelines on the perioperative management of OSA in 2012 (reviewed in October 2015).44 The guidelines noted that while some reports, in the literature have recommended routine screening for OSA prior to bariatric surgery, other reports have suggested clinical screening only does not result in any increase in postoperative pulmonary complications after laparoscopic Roux-en-Y gastric bypass, and that most current surgical practices refer patients with clinical symptoms of OSA for PSG, but do not make this a routine preoperative test prior to bariatric surgery. ASMBS provided, based on the evidence in the literature to date, the following guidelines on OSA in the bariatric surgery patient and its perioperative management:

1. “OSA is highly prevalent in the bariatric patient population....
2. [Patients with moderate to severe OSA] should bring their CPAP machines, or at least their masks, with them at the time of surgery and use them following bariatric surgery at the discretion of the surgeon.
3. Routine pulse oximetry or capnography for postoperative monitoring of patients with OSA after bariatric surgery should be utilized, but the majority of these patients do not routinely require an ICU [intensive care unit] setting.
4. No clear guidelines exist upon which to base recommendations for retesting for OSA following bariatric surgery....”

American Academy of Otolaryngology - Head and Neck Surgery
The American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) published guidelines on PSG for sleep-disordered breathing prior to tonsillectomy in children in 2011, which included the following45:

1. “Before determining the need for tonsillectomy, the clinician should refer children with SDB [sleep-disordered breathing] for PSG if they exhibit the following: obesity, Down syndrome, craniofacial abnormalities, neuromuscular disorders, sickle cell disease, or mucopolysaccharidosis.
2. The clinician should advocate for PSG prior to tonsillectomy for SDB in children without any of the comorbidities [listed above] for whom the need for surgery is uncertain or when there is discordance between tonsillar size of physical examination and the reported severity of SDB.
3. Clinicians should communicate PSG results to the anesthesiologist prior to the induction of anesthesia for tonsillectomy in a child with SDB.
4. Clinicians should admit children with OSA documented on PSG for inpatient, overnight monitoring after tonsillectomy if they are younger than age 3 years or have severe OSA.
(apnea-hypopnea index of 10 or more obstructive events/hour, oxygen saturation nadir less than 80% or both).

5. In children for whom PSG is indicated to assess SDB prior to tonsillectomy, clinicians should obtain laboratory-based PSG, when available.”

**American Thoracic Society**

In 2016, the American Thoracic Society (ATS) published a statement on the long-term effects and treatment of mild OSA in adults. One research question in the statement was to determine if treatment of mild OSA improved daytime sleepiness, quality of life, and reduced neurocognitive consequences. ATS’s systematic review concluded:

- **Daytime sleepiness:** subjective improvement with CPAP; unclear effect with non-CPAP therapies
- **Quality of life:** small improvements seen in different domains in different studies
- **Neurocognition:** treatment effects inconsistent.

**U.S. Preventive Services Task Force Recommendations**

In 2017, the U.S. Preventive Services Task Force (USPSTF) reviewed the evidence on screening for OSA in adults and concluded that “the current evidence is insufficient to assess the balance and harms of screening for obstructive sleep apnea (OSA) in asymptomatic adults. Evidence on screening tools to accurately detect persons in asymptomatic populations who should receive further testing and treatment of subsequently diagnosed OSA to improve health outcomes is lacking, and the balance of benefits and harms cannot be determined.”

**Medicare National Coverage**

The use of CPAP devices are covered under Medicare when ordered and prescribed by the licensed treating physician to be used in adults with OSA if either of the following criteria using the AHI or Respiratory Disturbance Index (RDI) are met:

- AHI or RDI of 15 events per hour or more,
- AHI or RDI between 5 and 14 events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.

AHI or RDI is equal to the average number of episodes of apnea and hypopnea per hour and must be based on a minimum of 2 hours of sleep using actual recorded number of hours of sleep (i.e., the AHI or RDI may not be extrapolated or projected). Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% oxygen desaturation.

In 2001, the Centers for Medicare & Medicaid Services (CMS) published a decision memorandum on CPAP that addressed how to define moderate-to-severe OSA as a guide to a coverage policy for CPAP. This review of the literature suggested that there is a risk of hypertension with an AHI greater than 15 events per hour, and thus treatment would be warranted for these patients without any additional signs and symptoms. For patients with an AHI between 5 and 15 events per hour and associated symptoms, CMS concluded that the data from 3 randomized controlled trials demonstrated improved daytime somnolence and functioning in those treated with CPAP.

In 2008, CMS expanded coverage of CPAP to include those beneficiaries with a diagnosis of OSA made with a combination of a clinical evaluation and unattended home sleep monitoring using a device with at least 3 channels. The coverage of CPAP would initially be limited to a 12-week period to identify beneficiaries diagnosed with OSA who benefit from CPAP. This was a change from prior coverage, which specified that PSG must be performed in a facility-based sleep study laboratory and not in a home or a mobile facility. CMS has defined AHI as the average number of episodes of apnea and hypopnea per hour of sleep, while the RDI is equal to the average number of respiratory disturbances per hour of continuous monitoring. There is
variability in the published medical literature about the definition of the events that constitute a respiratory disturbance, and, for the purposes of this national coverage decision, a respiratory disturbance was defined in the context of the sleep test technology of interest and, for portable monitoring devices that do not measure AHI or RDI directly, does not require direct measurement of airflow.

Effective in March 2008, CMS determined that CPAP therapy when used in adults with OSA would be considered reasonable and necessary under the following situations:

1. "The use of CPAP is covered under Medicare when used in adult patients with OSA. Coverage of CPAP is initially limited to a 12-week period to identify beneficiaries diagnosed with OSA as subsequently described who benefit from CPAP. CPAP is subsequently covered only for those beneficiaries diagnosed with OSA who benefit from CPAP during this 12-week period.

2. The provider of CPAP must conduct education of the beneficiary prior to the use of the CPAP device to ensure that the beneficiary has been educated in the proper use of the device. A caregiver, for example a family member, may be compensatory, if consistently available in the beneficiary's home and willing and able to safely operate the CPAP device.

3. A positive diagnosis of OSA for the coverage of CPAP must include a clinical evaluation and a positive:
   a. attended PSG performed in a sleep laboratory; or
   b. unattended HST [home sleep test] with a Type II home sleep monitoring device; or
   c. unattended HST with a Type III home sleep monitoring device; or
   d. unattended HST with a Type IV home sleep monitoring device that measures at least 3 channels.

4. The sleep test must have been previously ordered by the beneficiary’s treating physician and furnished under appropriate physician supervision.

5. An initial 12-week period of CPAP is covered in adult patients with OSA if either of the following criteria using the AHI or RDI are met:
   a. AHI or RDI greater than or equal to 15 events per hour, or
   b. AHI or RDI greater than or equal to 5 events and less than or equal to 14 events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.

6. The AHI or RDI is calculated on the average number of events of per hour. If the AHI or RDI is calculated based on less than 2 hours of continuous recorded sleep, the total number of recorded events to calculate the AHI or RDI during sleep testing must be at minimum the number of events that would have been required in a 2-hour period.

7. Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% oxygen desaturation.

8. Coverage with Evidence Development (CED): Medicare provides the following limited coverage for CPAP in adult beneficiaries who do not qualify for CPAP coverage based on criteria 1–7 above. A clinical study seeking Medicare payment for CPAP provided to a beneficiary who is an enrolled subject in that study must address one or more of the following questions:
   a. In Medicare-aged subjects with clinically identified risk factors for OSA, how does the diagnostic accuracy of a clinical trial of CPAP compare with PSG and Types II, III & IV HST in identifying subjects with OSA who will respond to CPAP?
   b. In Medicare-aged subjects with clinically identified risk factors for OSA who have not undergone confirmatory testing with PSG or Types II, III & IV HST, does CPAP cause clinically meaningful harm?"

In March 2009, CMS issued the following national coverage decision (CAG-00405N) for the types of sleep testing devices that would be approved for coverage.
CMS found that the evidence was sufficient to determine that the results of the sleep tests identified below can be used by a beneficiary’s treating physician to diagnose OSA:

1. “Type I PSG is covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed attended in a sleep lab facility.
2. A Type II or Type III sleep testing device is covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility, or attended in a sleep lab facility.
3. A type IV sleep testing device measuring three or more channels, one of which is airflow, is covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility, or attended in a sleep lab facility.
4. Sleep testing devices measuring three or more channels that include actigraphy, oximetry, and peripheral arterial tone, are covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility, or attended in a sleep lab facility.”

Ongoing and Unpublished Clinical Trials
A search of ClinicalTrials.gov in May 2017 identified over 200 studies on diagnosis and medical management of OSA.

References


### Documentation for Clinical Review

Please provide the following documentation (if/when requested):

- History and physical and/or consultation notes including:
  - Documentation of obstructive sleep apnea including:
    - AHI/RDI
    - Symptoms
    - Comorbidities
  - Type of sleep study that is being requested
  - Reason for requested study
  - Current treatment plan
  - Prior treatment and response (including documented failed trial of CPAP; if applicable)
  - Documented sleep test results (e.g., Epworth Sleepiness Scale, Berlin Questionnaire, STOP Bang); if applicable
  - Prior Polysomnography or Sleep study reports; if applicable
  - Sleep specialty physician recommendation and prescription for positive airway pressure device or intraoral appliance; if applicable

### Post Service

- Polysomnography or Home Sleep study reports
- Operative report(s); if applicable

### Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to benefit design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement.

**MN/IE**

The following services may be considered medically necessary in certain instances and investigational in others. Services may be considered medically necessary when policy criteria...
are met. Services may be considered investigational when the policy criteria are not met or when the code describes application of a product in the position statement that is investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>94660</td>
<td>Continuous positive airway pressure ventilation (CPAP), initiation and management</td>
</tr>
<tr>
<td></td>
<td>94762</td>
<td>Noninvasive ear or pulse oximetry for oxygen saturation; by continuous overnight monitoring (separate procedure)</td>
</tr>
<tr>
<td></td>
<td>95782</td>
<td>Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist</td>
</tr>
<tr>
<td></td>
<td>95783</td>
<td>Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist</td>
</tr>
<tr>
<td></td>
<td>95800</td>
<td>Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time</td>
</tr>
<tr>
<td></td>
<td>95801</td>
<td>Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (e.g., by airflow or peripheral arterial tone)</td>
</tr>
<tr>
<td></td>
<td>95805</td>
<td>Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness</td>
</tr>
<tr>
<td></td>
<td>95806</td>
<td>Sleep study, unattended, simultaneous recording of heart rate, oxygen saturation, respiratory airflow, and respiratory effort (e.g., thoracoabdominal movement)</td>
</tr>
<tr>
<td></td>
<td>95807</td>
<td>Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist</td>
</tr>
<tr>
<td></td>
<td>95808</td>
<td>Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist</td>
</tr>
<tr>
<td></td>
<td>95810</td>
<td>Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist</td>
</tr>
<tr>
<td></td>
<td>95811</td>
<td>Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist</td>
</tr>
<tr>
<td>HCPCS</td>
<td>A7027</td>
<td>Combination oral/nasal mask, used with continuous positive airway pressure device, each</td>
</tr>
<tr>
<td></td>
<td>A7028</td>
<td>Oral cushion for combination oral/nasal mask, replacement only, each</td>
</tr>
<tr>
<td></td>
<td>A7029</td>
<td>Nasal pillows for combination oral/nasal mask, replacement only, pair</td>
</tr>
<tr>
<td></td>
<td>A7034</td>
<td>Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap</td>
</tr>
<tr>
<td></td>
<td>A7035</td>
<td>Headgear used with positive airway pressure device</td>
</tr>
<tr>
<td></td>
<td>A7036</td>
<td>Chinstrap used with positive airway pressure device</td>
</tr>
<tr>
<td></td>
<td>A7037</td>
<td>Tubing used with positive airway pressure device</td>
</tr>
<tr>
<td></td>
<td>A7038</td>
<td>Filter, disposable, used with positive airway pressure device</td>
</tr>
<tr>
<td></td>
<td>A7039</td>
<td>Filter, nondisposable, used with positive airway pressure device</td>
</tr>
<tr>
<td></td>
<td>A7047</td>
<td>Oral interface used with respiratory suction pump, each</td>
</tr>
<tr>
<td></td>
<td>E0470</td>
<td>Respiratory assist device, bi-level pressure capability, without backup rate feature, used with noninvasive interface, e.g., nasal or facial</td>
</tr>
<tr>
<td>Type</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td>E0471</td>
<td>Respiratory assist device, bi-level pressure capability, with back-up rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)</td>
</tr>
<tr>
<td></td>
<td>E0485</td>
<td>Oral device/appliance used to reduce upper airway collapsibility, adjustable or nonadjustable, prefabricated, includes fitting and adjustment</td>
</tr>
<tr>
<td></td>
<td>E0486</td>
<td>Oral device/appliance used to reduce upper airway collapsibility, adjustable or nonadjustable, custom fabricated, includes fitting and adjustment</td>
</tr>
<tr>
<td></td>
<td>E0561</td>
<td>Humidifier, nonheated, used with positive airway pressure device</td>
</tr>
<tr>
<td></td>
<td>E0562</td>
<td>Humidifier, heated, used with positive airway pressure device</td>
</tr>
<tr>
<td></td>
<td>E0601</td>
<td>Continuous positive airway pressure (CPAP) device</td>
</tr>
<tr>
<td></td>
<td>G0398</td>
<td>Home sleep study test (HST) with type II portable monitor, unattended; minimum of 7 channels: EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort and oxygen saturation</td>
</tr>
<tr>
<td></td>
<td>G0399</td>
<td>Home sleep test (HST) with type III portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate and 1 oxygen saturation</td>
</tr>
<tr>
<td></td>
<td>G0400</td>
<td>Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels</td>
</tr>
</tbody>
</table>

**ICD-10 Procedure**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4A1ZXQZ</td>
<td>Monitoring of Sleep, External Approach</td>
</tr>
<tr>
<td>5A09357</td>
<td>Assistance with Respiratory Ventilation, Less than 24 Consecutive Hours, Continuous Positive Airway Pressure</td>
</tr>
<tr>
<td>5A09358</td>
<td>Assistance with Respiratory Ventilation, Less than 24 Consecutive Hours, Intermittent Positive Airway Pressure</td>
</tr>
<tr>
<td>5A0935Z</td>
<td>Assistance with Respiratory Ventilation, Less than 24 Consecutive Hours</td>
</tr>
<tr>
<td>5A09457</td>
<td>Assistance with Respiratory Ventilation, 24-96 Consecutive Hours, Continuous Positive Airway Pressure</td>
</tr>
<tr>
<td>5A09458</td>
<td>Assistance with Respiratory Ventilation, 24-96 Consecutive Hours, Intermittent Positive Airway Pressure</td>
</tr>
<tr>
<td>5A0945Z</td>
<td>Assistance with Respiratory Ventilation, 24-96 Consecutive Hours</td>
</tr>
<tr>
<td>5A09557</td>
<td>Assistance with Respiratory Ventilation, Greater than 96 Consecutive Hours, Continuous Positive Airway Pressure</td>
</tr>
<tr>
<td>5A09558</td>
<td>Assistance with Respiratory Ventilation, Greater than 96 Consecutive Hours, Intermittent Positive Airway Pressure</td>
</tr>
<tr>
<td>5A0955Z</td>
<td>Assistance with Respiratory Ventilation, Greater than 96 Consecutive Hours</td>
</tr>
</tbody>
</table>

**ICD-10 Diagnosis**

All Diagnoses

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/03/2009</td>
<td>Policy title change</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Policy revision with position change</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Policy combined:</td>
<td>Medical Policy Committee</td>
</tr>
</tbody>
</table>
Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/18/2009</td>
<td>Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome</td>
<td>Administrative Review</td>
</tr>
<tr>
<td></td>
<td>Obstructive Sleep Apnea Surgeries</td>
<td></td>
</tr>
<tr>
<td>01/19/2010</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>10/01/2010</td>
<td>Policy title change from Diagnosis and Treatment Services for Obstructive Sleep Apnea (OSA) and Upper Airway Resistance Syndrome (UARS)</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td></td>
<td>Policy revision with position change</td>
<td></td>
</tr>
<tr>
<td>01/21/2011</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>04/12/2011</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>07/22/2011</td>
<td>Policy revision with position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>08/10/2011</td>
<td>Administrative Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>01/11/2013</td>
<td>Policy criteria clarification and revision</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>02/22/2013</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>07/03/2013</td>
<td>Policy criteria clarification and revision</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>01/30/2015</td>
<td>Policy title change from Obstructive Sleep Apnea - Diagnosis and Management</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td></td>
<td>Policy revision with position change effective 3/30/2015</td>
<td></td>
</tr>
<tr>
<td>03/30/2015</td>
<td>Policy revision with position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>08/31/2015</td>
<td>Coding update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>02/01/2016</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>03/01/2016</td>
<td>Policy Guideline clarification</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>02/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>10/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
</tbody>
</table>

**Definitions of Decision Determinations**

**Medically Necessary:** A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.
Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.